Cargando…

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Sodium glucose cotransporter 2 (SGLT2) inhibitors, an antidiabetic drug, promotes urinary excretion of glucose by blocking its reabsorption in the renal proximal tubules. It is unclear whether SGLT2 inhibition could attenuate nonalcoholic steatohepatitis (NASH) and NASH-associated hepatocellular car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiba, Kumiko, Tsuchiya, Kyoichiro, Komiya, Chikara, Miyachi, Yasutaka, Mori, Kentaro, Shimazu, Noriko, Yamaguchi, Shinobu, Ogasawara, Naomi, Katoh, Makoto, Itoh, Michiko, Suganami, Takayoshi, Ogawa, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5799179/ https://www.ncbi.nlm.nih.gov/pubmed/29402900 http://dx.doi.org/10.1038/s41598-018-19658-7

Ejemplares similares

A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition
por: Miyachi, Yasutaka, et al.
Publicado: (2018)

Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
por: Komiya, Chikara, et al.
Publicado: (2017)

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
por: Komiya, Chikara, et al.
Publicado: (2016)

Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice
por: Mori, Kentaro, et al.
Publicado: (2019)

Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH
por: Kanamori, Yohei, et al.
Publicado: (2021)

Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver
por: Itoh, Michiko, et al.
Publicado: (2020)

Differential effect of canagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice
por: Otsuka, Hiroko, et al.
Publicado: (2022)

Adipose Tissue Remodeling as Homeostatic Inflammation
por: Itoh, Michiko, et al.
Publicado: (2011)

Molecular mechanism of obesity‐induced ‘metabolic’ tissue remodeling
por: Tanaka, Miyako, et al.
Publicado: (2017)

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
por: Haas, B, et al.
Publicado: (2014)

Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH
por: Itoh, Michiko, et al.
Publicado: (2023)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart
por: Lim, Ven G., et al.
Publicado: (2019)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
por: Kellon, Eleanor M., et al.
Publicado: (2022)

Molecular mechanism of crosstalk between immune and metabolic systems in metabolic syndrome
por: Hachiya, Rumi, et al.
Publicado: (2022)

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy
por: Ali, Amr, et al.
Publicado: (2023)

Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles
por: Watanabe, Takayuki, et al.
Publicado: (2020)

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor
por: Furuhashi, Masato, et al.
Publicado: (2016)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert, Jochen
Publicado: (2015)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

SGLT2 Inhibitors—A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling
por: Yagi, Takashi, et al.
Publicado: (2022)

Antiobesity Effect of Eicosapentaenoic Acid in High-Fat/High-Sucrose Diet–Induced Obesity: Importance of Hepatic Lipogenesis
por: Sato, Ayumi, et al.
Publicado: (2010)

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma
por: Jojima, Teruo, et al.
Publicado: (2019)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)
por: Goto, Ryo, et al.
Publicado: (2019)

Forkhead box class O family member proteins: The biology and pathophysiological roles in diabetes
por: Tsuchiya, Kyoichiro, et al.
Publicado: (2017)

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
por: Goto, Toshihiro, et al.
Publicado: (2018)

Canagliflozin, an Inhibitor of the Na(+)-Coupled D-Glucose Cotransporter, SGLT2, Inhibits Astrocyte Swelling and Brain Swelling in Cerebral Ischemia
por: Shim, Bosung, et al.
Publicado: (2023)

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2019)

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
por: Maki, Toshinobu, et al.
Publicado: (2019)

Eicosapentaenoic Acid Ameliorates Non-Alcoholic Steatohepatitis in a Novel Mouse Model Using Melanocortin 4 Receptor-Deficient Mice
por: Konuma, Kuniha, et al.
Publicado: (2015)

Response to Comment on: Satoh-Asahara et al. Highly Purified Eicosapentaenoic Acid Increases Interleukin-10 Levels of Peripheral Blood Monocytes in Obese Patients With Dyslipidemia. Diabetes Care 2012;35:2631–2639
por: Satoh-Asahara, Noriko, et al.
Publicado: (2013)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Canagliflozin – Beginning of the journey
por: Pandey, Sunil Kumar, et al.
Publicado: (2014)

A case of NASH with genetic predisposition successfully treated with an SGLT2 inhibitor: a possible involvement of mitochondrial dysfunction
por: Nakajima, Rikako, et al.
Publicado: (2022)

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
por: Weir, Matthew R, et al.
Publicado: (2020)

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
por: Maruyama, Takashi, et al.
Publicado: (2019)

Crystal structure of canagliflozin hemihydrate
por: Liu, Kai-Hang, et al.
Publicado: (2016)

Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model
por: Hosokawa, Yusei, et al.
Publicado: (2023)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3d2l4khecddrodl934iib5543d